Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02934477 · ClinicalTrials.gov registry record
Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
A clinical trial of Myelofibrosis, sponsored by Center for International Blood and Marrow Transplant Research.
- Recruiting
- Registry status
- 650
- Enrollment target
- 1
- Study location
NCT02934477: Recruiting study of Myelofibrosis, sponsored by Center for International Blood and Marrow Transplant Research.
NCT02934477 is a study of Myelofibrosis that is actively recruiting participants, run by Center for International Blood and Marrow Transplant Research. The registered enrollment target is 650 participants, above the 185-participant average among 61 other Myelofibrosis trials with a reported enrollment target (251% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02934477, a study of Myelofibrosis, is actively recruiting participants, sponsored by Center for International Blood and Marrow Transplant Research.
- RECRUITING
- Registry status
- 650 participants
- Enrollment target
- 1
- Study location
Study Summary
This observational study will compare outcomes of a prospectively-enrolled cohort of Hematopoietic Stem Cell Transplant (HCT) recipients with outcomes of a cohort of age-matched historical non-HCT controls. Patients undergoing alloHCT will receive HCT in a US transplant center and be reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) using well-established CIBMTR report forms and data collection procedures as well as a study-specific supplemental form. Data on the historical non-HCT controls will be collected at 14 US academic centers. These centers will provide data on all consecutive patients with PMF, post-ET MF, or post-PV MF referred to their institutions between 2000 and 2012.
Primary Outcome
Compare the five-year survival probabilities from DIPSS assessment between the two study arms: alloHCT recipients (arm 1) and non-HCT therapies (ruxolitinib / best supportive care) recipients (arm 2).
Conditions Studied
Interventions
- OTHER Hematopoietic Stem Cell Transplant
Study Locations (1)
Minnesota
- Center for International Blood and Marrow Transplant Research - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 650 participants |
| Start Date | 2016-11 |
| Est. Completion | 2027-10 |
What NCT02934477 shows while recruiting
NCT02934477 is an observational study that tracks outcomes without assigning an intervention. The registered 650 participants enrollment target is mid-sized for trials with a published cap, above the 185-participant average among 61 other Myelofibrosis trials with a reported enrollment target (251% higher).
The record links to 1 condition, with Myelofibrosis appearing as the primary indexed condition, and to 1 intervention - of which Hematopoietic Stem Cell Transplant is the first listed.
NCT02934477 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT02934477 about?
NCT02934477 is a clinical study titled "Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis". This observational study will compare outcomes of a prospectively-enrolled cohort of Hematopoietic Stem Cell Transplant (HCT) recipients with outcomes of a cohort of age-matched historical non-HCT controls. Patients undergoing alloHCT will receive HCT in a US transplant center and be reported to the...
What is the current status of trial NCT02934477?
This trial is currently recruiting. The enrollment target is 650 participants. The study started on 2016-11. Estimated completion is 2027-10.
What conditions does trial NCT02934477 study?
This clinical trial studies the following conditions: Myelofibrosis.
What interventions are being tested in trial NCT02934477?
The interventions under investigation include: Hematopoietic Stem Cell Transplant (OTHER).
Who is sponsoring clinical trial NCT02934477?
This trial is sponsored by Center for International Blood and Marrow Transplant Research, which has 29 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02934477 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02934477's enrollment target sits among peer trials
650 2nd of 61 the highest of 61 other Myelofibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myelofibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
RECRUITING · Phase 1
-
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
RECRUITING · Phase 2
-
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
RECRUITING · Phase 3
-
Momelotinib During and After HCT in Myelofibrosis
RECRUITING · Phase 1
-
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
RECRUITING · Phase 1
-
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04579120 · 650 participants
Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)
- NCT04875702 · 650 participants · Phase 4
Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
- NCT05046600 · 650 participants
Registry of Arthrex Hand and Wrist Products
- NCT05253235 · 650 participants · NA
Health and Resilience Projects: Foundations
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia